An instrument-based screening assay for DNA-targeted anticancer drugs using resonance light scattering
Related Experiment Video
Updated: Jun 16, 2026
Assessment of DNase Activity by Ratiometric Fluorescence Resonance Energy Transfer
Published on: July 25, 2025
Zhanguang Chen1, Guoliang Liu, Maohuai Chen
1Department of Chemistry, Shantou University, Shantou, China. kqlu@stu.edu.cn
Abstract:
DNA is a valid drug target for development of target-based therapeutics against cancer. Screening DNA-targeted anticancer drugs is a key process for the research and development of new anticancer drugs. The traditional anticancer drug screening methods, including animal experiments and cell-based screening assays, have unavoidable drawbacks. In this contribution, the new instrument-based screening assay for DNA-targeted anticancer drugs in vitro using resonance light scattering (RLS) technique was proposed. The experiments suggested that the increment of RLS intensity was directly proportional to the antitumor effect of anticancer drugs. Therefore, it was intuitive to obtain the sequence of the antitumor activity of four anticancer drugs without data processing as follows: mitoxantrone (MIT) > pirarubicin (PIR) > daunorubicin (DAU) > doxorubicin (DOX) by RLS screening spectra. Moreover, the apparent equilibrium constant (K) was 1.23 x 10(4), 2.22 x 10(4), 4.66 x 10(4) L/mol for DOX, DAU, and PIR, respectively. The inhibitory concentration 50 (IC50) was 0.148, 0.102, 0.025, 0.013 micromol/L for DOX, DAU, PIR, MIT, respectively. Therefore, the antitumor effect of four drugs was as follows: MIT > PIR > DAU > DOX, which was in good agreement with the result obtained from RLS screening assays. The mechanism between DNA and anthracycline drugs was investigated using UV-vis spectroscopy, fluorescence spectroscopy, and electrophoresis experiments. The proposed assay is a rapid, intuitive, and easy-to-conduct bioassay with good accuracy and reproducibility.
Insights
A new in vitro assay using resonance light scattering (RLS) effectively screens DNA-targeted anticancer drugs. This method provides an intuitive ranking of drug efficacy, overcoming limitations of traditional screening methods.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Pharmacology
Background:
- DNA is a crucial target for developing novel anticancer therapeutics.
- Traditional methods for screening DNA-targeted anticancer drugs, such as animal and cell-based assays, have significant limitations.
- Efficient and accurate screening methods are essential for advancing cancer drug development.
Purpose of the Study:
- To introduce a novel instrument-based in vitro screening assay for DNA-targeted anticancer drugs.
- To utilize the resonance light scattering (RLS) technique for drug screening.
- To evaluate the antitumor activity and mechanism of action of selected anticancer drugs.
Main Methods:
- Development and application of a resonance light scattering (RLS) based screening assay.
- In vitro analysis of DNA-targeted anticancer drugs, including mitoxantrone, pirarubicin, daunorubicin, and doxorubicin.
- Characterization of drug-DNA interactions using UV-vis spectroscopy, fluorescence spectroscopy, and electrophoresis.
Main Results:
- The RLS intensity directly correlated with the antitumor effect of the drugs.
- The study intuitively determined the order of antitumor activity: mitoxantrone > pirarubicin > daunorubicin > doxorubicin.
- Apparent equilibrium constants (K) and inhibitory concentrations 50 (IC50) values were determined, confirming the drug efficacy order.
Conclusions:
- The proposed RLS-based assay is a rapid, intuitive, and accurate method for screening DNA-targeted anticancer drugs.
- The assay demonstrates good reproducibility and offers an alternative to traditional screening approaches.
- The findings contribute to the advancement of target-based cancer therapeutics development.
